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Extensive research has shown that people suffering with rheumatoid arthritis (RA) are at a 
substantially increased risk for morbidity and mortality from cardiovascular (CV) disease. 
Although this connection is widely accepted by rheumatology experts, primary care providers 
are often tasked with CV risk management of the RA patient and they may not be fully aware of 
the increased risk. The lack of clear clinical guidelines for CV management in this population 
has led to under diagnosis and under treatment of CV risk factors. The case presented in this 
report will follow Mr. Foster, a 59 year old man with RA and uncontrolled hypertension. Mr. 
Foster presented to the clinic with influenza like illness but an uncontrolled blood pressure was 
noted at the visit. The goal of this case report will be to define appropriate CV risk detection and 
management for Mr. Foster and best practices for management of CV risks in the setting of RA. 
A current literature review was performed using Pub Med, Clinical Key, and CINAHL search 
engines to ascertain the best evidence based practices for assessing and managing CV risk in RA 
patients. This report will not include discussion of lifestyle modifications or diabetes screening 
and management, but these topics should not be downplayed in the CV risk management of this 
population. This report will conclude with five CV risk management techniques for the primary 
care provider.  
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Cardiovascular Risk Management for Patients with Rheumatoid Arthritis: A Case Report 
Background 
 The case of Mr. Foster presented a treatment challenge in the management of rheumatoid 
arthritis (RA) and cardiovascular (CV) disease. He is a 59 year old man with RA and 
uncontrolled hypertension. He is currently prescribed Lisinopril by his primary care provider but 
reports that he almost exclusively sees his rheumatologist and rarely follows up with primary 
care. He reports that his rheumatologist doesn’t tend to screen or counsel about hypertension, 
diabetes, or high cholesterol, but mainly focuses on RA symptoms and medications. Mr. Foster 
noted that his blood pressure always runs around 140/90 and he thought that was acceptable. Mr. 
Foster’s situation raises the question of whether RA increases the risk of CV disease and how to 
best manage the increased risks in this population. Mr. Foster’s situation also raises the issue that 
rheumatology specialists may not be appropriately managing or communicating this increased 
risk and the responsibility might fall to primary care providers.  
According to Rempenault et al. (2017) patients with rheumatoid arthritis have an 
increased risk of CV disease when compared to the general population. A recent meta-analysis of 
24 RA mortality studies found that patients with RA have a 50 percent increased risk of CV 
related death than those without RA (Dadoun et al., 2013). The increased risk of CV disease is 
primarily due to the chronic inflammation that accompanies RA as well as the traditional risk 
factors (Hansen, 2018). The inflammation associated with RA has been proven to lead to 
accelerated atherosclerosis (Hansen, 2018). Many studies have found that the risk of CV disease 
in RA is equivalent to the CV risks associated with diabetes mellitus (Bartels et al., 2016).  
Despite the widespread knowledge that CV risks are increased in the RA patient, there 
are still gaps in care for this population and, compared to their peers, RA patients receive less 
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stringent management of lipids, hypertension, and diabetes mellitus (Bartels et al., 2016). 
According to Bartels et al. (2016) the disparities in care for this population could include gaps in 
RA knowledge by primary care providers. In one survey only 32 percent of primary care 
providers were aware of the increased CV risks in RA patients (Bartels et al., 2016). On the other 
side, rheumatology specialists were very aware of the increase CV risks but did not feel 
comfortable or have time to manage hypertension, diabetes, and hyperlipidemia in the specialty 
setting (Bartels et al., 2016). This lack of aggressive management on either side has led to 
preventative care gaps in this at-risk population (Bartels et al., 2016). To lend to this treatment 
challenge is the fact that CV risk management professional guidelines for the RA patient are 
vague and identifying at risk patients is not clearly outlined in current guidelines (Bartels et al., 
2016). Appropriate CV risk identification and management in the RA patient is the purpose of 
this case report.  
Case Report 
Mr. Foster is a 59 year old man who presented to the clinic with complaints of fever, 
chills, headache, cough, sore throat, and body aches. The onset of his symptoms began five days 
ago, and the symptoms haven’t worsened or improved since that time. He described his cough as 
a persistent dry “nagging” cough. The cough did tend to keep him up at night and he had to call 
in sick to work for the past 2 days due to lack of sleep.  He reported his pain as generalized mild 
muscle aches but described his headache as “severe”. Rest improved his symptoms slightly, and 
he had also been using ibuprofen to control fever and muscle aches with mild relief. He reported 
he had also been using over the counter cough syrup with little effect on his harsh cough. He 
denied recent sick contacts although he does work at a retail job and is around many different 
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people who present to the store every day. He presented to the clinic because his symptoms were 
not improving and they were affecting his productivity and keeping him out of work. 
 Mr. Foster’s medical history includes the diagnosis of RA and hypertension. He follows 
with a rheumatologist for his RA and reported that his symptoms have been in excellent control.  
He denied surgical history. He also denied tobacco, alcohol, and drug use and abuse. He drinks 
approximately 1 cup of coffee per day.  He is married with grown children who are all in good 
health.   
 Mr. Foster denied allergies. He is currently prescribed and taking Lisinopril 10 mg daily, 
Humira 40 mg injection every 2 weeks, Methotrexate 10 mg injection every week, and a daily 
multivitamin supplement. He reported taking his medications as prescribed with no obvious side 
effects.  
 The review of systems was negative except for the symptoms listed in his history of 
present illness. He reported the 5 day history of sore throat, runny nose, fever, headache, body 
aches, and cough. He denied shortness of breath, chest pain, swelling in legs, rashes and night 
sweats. He denied joint pain and swelling and reports that his RA is in excellent control on 
current medication regimen.  
 Vital signs included a heart rate of 90, respiratory rate of 30, temperature of 102.4, and 
blood pressure of 140/90. A repeat blood pressure later in the visit revealed a reading of 142/92. 
He stated that is blood pressure normally runs around 140 systolic. His primary care provider 
prescribed the Lisinopril but he reported that he doesn’t follow up with his primary provider as 
much as he does his rheumatologist. He stated that his rheumatologist doesn’t normally address 
his blood pressure, cholesterol, or other screenings but mostly concentrates on his RA symptoms 
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and medications. Mr. Foster could not remember the last time he had routine labs screening his 
cholesterol and for diabetes.  
 His physical exam was unremarkable besides rhinorrhea. Differential diagnoses included 
pneumonia, influenza, or viral upper respiratory infection. The patient did receive his flu shot 
this season but is on immunosuppressant medications for his RA. Mr. Foster was swabbed for 
influenza which came back positive. He was given a prescription for Tamiflu due to his chronic 
immunosuppression. He was advised to stay home and was instructed about supportive cares 
including adequate rest, nutrition, fluids, and completing the Tamiflu prescription. He was 
instructed to follow up if his symptoms were not improving in 48 hours or if he developed 
shortness of breath or chest pain. A chest x-ray would be completed if he is not improving to rule 
out concurrent pneumonia.  Mr. Foster was also encouraged to set up a return visit in 2 weeks to 
address his uncontrolled hypertension and other CV risks. This leads to the question if CV risk 
management is different for the RA patient and how to best conduct his follow up visit. The 
literature review will address appropriate CV risk management for patients with RA in the 
primary care setting.  
Literature Review 
 
 The aforementioned information necessitates aggressive and targeted CV risk 
management in patients with RA. This literature review will address the current literature and 
formulate an action plan for CV risk management in the primary care setting. One of the top 
recommendations found in a majority of the current literature is that lowering RA disease 
activity reduces CV risk (Barber et al., 2015).  Barber et al. (2015) performed a systematic 
review of current guidelines on this topic and revealed that they all included recommendations 
for early treatment of RA to reduce symptoms, inflammation, and CV risk. The 2015/2016 
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guidelines from the European League Against Rheumatism (EULAR) agreed with this 
recommendation and went even further to say that RA patients should be treated with disease-
modifying antirheumatic drugs (DMARDs) early in the disease course and long-term to reduce 
CV risk (Agca et al., 2017). Chodara, Wattiaux, and Bartels (2017) found that control of RA 
disease with a “treat to target” approach should be managed by a specialist of rheumatology for 
the best RA and CV outcomes. Mr. Foster is appropriately managed by a rheumatologist and is 
on methotrexate (a DMARD) and Humira (a Tumor Necrosis Factor (TNF) Inhibitor), he denies 
joint pain and reports his disease is “under control”. Methotrexate is the frontline treatment for 
RA and has been found through a systematic literature review by Westlake et al. (2010) to 
reduce CV risks in RA patients by decreasing inflammation that may accelerate atherosclerosis. 
In fact, those never treated with methotrexate had increased risk of CV death by 70 percent 
compared to patients treated with the medication (Westlake et al., 2010). Westlake et al., (2010) 
also described that patients on methotrexate were found to have improved physical functioning 
and mobility which may increase exercise tolerance, decrease body mass, and had the 
opportunity to decrease CV risk through lifestyle modification. 
 Patients on DMARD therapy such as methotrexate are frequently able to decrease their 
use of other medications such as NSAIDS and glucocorticoids which can positively impact their 
CV risk (Westlake et al., 2010). NSAIDS have been proven to be associated with increased risk 
of CV mortality and events (Westlake et al., 2010). Glucocorticoids have also shown a negative 
impact on hypertension, dyslipidemia, and weight gain, increasing CV risk (Westlake et al., 
2010).  The PRECISION-ABPM study is a large double blind randomized trial of 444 patients 
that found ibuprofen was associated with a significant increase in systolic blood pressure 
compared to naproxen or celecoxib (Ruschitzka et al., 2017). The PRECISION-ABPM study 
CARDIOVASCULAR RISK MANAGEMENT  9 
 
also found that ibuprofen increased blood pressure 3 mm Hg on average, increased new 
incidence of hypertension, and made already existing hypertension more difficult to manage 
(Ruschitzka et al., 2017). These findings are clinically relevant because it has been found that a 
decrease of systolic blood pressure by just 2 mm Hg can decrease risk or stroke by 10 percent 
and ischemia by 7 percent (Ruschitzka et al., 2017). According to a systematic review of RA 
guidelines Barber et al., (2015) found that five separate guidelines all addressed NSAIDS and the 
consensus was that they increased CV risk in the RA patient and should be avoided in known or 
high risk CV disease. If use cannot be avoided, consider using the lowest dose for the shortest 
period of time. Mr. Foster does use ibuprofen and he should be counseled on the increased risk 
this places him at for CV disease, especially with uncontrolled hypertension. NSAID counseling 
and monitoring is an essential factor of CV risk management in the RA patient.  
 CV risk assessment is a topic with many varying guidelines and expert opinions. All of 
the current guidelines advocate for some type of risk assessment because calculation of CV risk 
leads to early identification of risk factors so that intervention can begin (Chodara et al., 2017). 
Risk assessments developed for the general population such as the Framingham Risk Score 
(FRS) and the Reynolds Risk Score (RRS) do not take into account specific RA risks and 
therefore have been found to underestimate CV risk in the RA patient (Symmons, 2015). The 
FRS and RRS use values such as age, gender, smoking status, blood pressure, diabetes status, 
and lipid levels and then assign the patient a score to calculate the patients 10 year risk of CV 
events (Agca et al., 2017). A number of RA specific CV risk score calculators have been 
developed such as the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA), the 
EULAR 1.5 multiplier and the QRISK2 (Crowson et al., 2017). According to Crowson et al., 
(2017) after a validation analysis of patients from seven countries, the QRISK2, EULAR 1.5 
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multiplier and the ERS-RA algorithms did not more accurately predict CV risk than general risk 
calculators such as the FRS and RRS.  
Because the evidence does not pinpoint the most effective CV risk calculator, most of the 
guidelines have leaned on expert opinion to make their final recommendations. The 2017 
EULAR task force addresses the problem by recommending the application of a 1.5 multiplier to 
general population risk prediction models in order to estimate the increased risk of CV disease in 
all RA patients (Agca et al., 2017).  The previous guidelines from EULAR limited the use of the 
multiplier only to those with RA whom met certain criteria, but when research results found it 
was still under-predicting CV risk, they amended the guideline in 2017 to include every patient 
with RA (Agca et al., 2017). The EULAR multiplier is also thought to be more user friendly and 
does not make a practitioner use a different risk assessment than they do for the general 
population (Agca et al., 2017). EULAR also amended this recommendation because studies have 
shown that CV risks are increased in every RA patient, even those newly diagnosed or in the 
early stages of the disease (Agca et al., 2017). The EULAR recommendations found that CV risk 
assessment should be completed within 1-2 years of disease onset and then, if the patient is at 
low-moderate risk, they should be reassessed at least once every 5 years (Agca et al, 2017). 
Quality indicators released by the Canadian Institutes of Health Research also concurred with 
this recommendation and advised screening at least once every 5 years if at low risk based on 
CV predictor score (Barber et al. 2015). The recent clinical update by Chodara et al., (2017) 
critically reviewed all of the current research from the past 5 years on this topic and also 
recommended the EULAR multiplier but they did address that there remains a need for a 
“validated, user-friendly estimation of CVD risk in patients with RA” (para. 6). In conclusion 
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until a RA specific CV risk calculator is available and validated as useful, most guidelines 
suggest the EULAR multiplier and CV risk calculators designed for the general population.  
One of the major modifiable risk factors for CV disease is hypertension and the 
prevalence in RA patients has been found to be higher than the general population (Panoulas, 
John, & Kitas, 2008). Not only is the prevalence of hypertension increased but the management 
and control of hypertension in the RA population is less than adequate (Panoulas et al, 2008). 
The increased risk of hypertension in RA is multifactorial and is linked to inflammation, physical 
inactivity due to joint pain, and frequently used medications such as NSAIDS and corticosteroids 
(Pall, Szanto, & Farsang, 2013). NSAIDS and corticosteroids have also been found to inhibit the 
antihypertensive effects of medications, including diuretics, ACE/ARB, and beta blockers (Pall 
et al., 2013). There are currently no recommendations on which anti-hypertensives are preferred 
in RA patients and no evidence that treatment thresholds should vary from that of the general 
population (Agca et al., 2017). The current national guidelines from the American College of 
Cardiology/American Heart Association (ACC/AHA) advise screening all adults yearly for 
hypertension, but rheumatology guidelines aim for a blood pressure screening at 80 percent of all 
visits (Barber et al., 2016). The ACC/AHA guidelines for hypertension management suggest that 
lifestyle modifications should be prescribed to all patients with elevated blood pressure, these 
include salt restriction, weight loss, The Dietary Approaches to Stop Hypertension (Dash) diet, 
exercise, and limited alcohol intake (Basile & Block, 2018). The ACC/AHA guidelines also 
suggest treating blood pressure over 140/90 in all adults when using in office readings, 
ambulatory or home monitoring blood pressure should be treated to a goal of 130/80. (Basile & 
Block, 2018). Patients with RA have a similar risk of CV disease as patients with diabetes, and 
the diabetes association also follows the 140/90 guidelines unless high risk or current CV 
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disease, then a target of 130/80 is more appropriate if the patient can tolerate the treatment 
without side effects (de Boer et al., 2017). The Joint National Committee (JNC 8) guidelines on 
HTN recommend treatment for a blood pressure >150/90 in adults >60 years or >140/90 in 
younger adults regardless of comorbidities such as diabetes or RA (Chodara et al., 2017). In Mr. 
Foster’s case his hypertension is uncontrolled at levels over 140/90 and with his high CV risk 
with RA he might benefit from a blood pressure closer to 130/80 per ACC/AHA and ADA 
recommendations. Clinical trials have demonstrated 4 classes of medication that should be 
considered for initial hypertension treatment and they include thiazide diuretics, long acting 
calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin 2 
receptor blockers (ARBs) (de Boer et al., 2017). Mr. Foster is currently on Lisinopril which is an 
appropriate first line therapy, but his blood pressure is uncontrolled so the dose should be 
increased or a second agent could be added (de Boer et al., 2017). Mr. Foster needs close follow 
up on his blood pressure at every office visit and adjustment in therapy as needed according to 
current guidelines.  
Another CV risk factor that needs to be assessed at Mr. Foster’s follow up visit is his 
lipid levels. Lipid levels are an integral piece of CV risk recognition and should ideally be 
measured when RA disease is stable and well controlled (Agca et al., 2017). Patients with active 
RA disease tend to have paradoxical lipid levels. Although their CV risk is increased, they tend 
to have lower total cholesterol (TC) and low density lipoprotein (LDL) levels compared to the 
general population (Agca et al., 2017). Patients with active disease tend to have higher 
triglyceride levels and low high-density lipoprotein (HDL) levels, therefore the TC/HDL ratio is 
a better predictor for CV risk outcomes in the RA population (Agca et al., 2017). Statins are the 
treatment of choice for dyslipidemia in the RA population, they have been found to reduce CV 
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risk and have anti-inflammatory effects (Saoulaidopoulos, Nikiphorou, Dimitroulas, & Kitas, 
2018). The results of two trials, the TRACE (Trial of Atorvastatin for Primary Prevention of 
Cardiovascular Events in RA and the TARA (Trial of Atorvastatin in RA), on the statin effect in 
RA patients found decreased arthritis symptoms and lipid levels., The trials also found that 
patients who were taken off statin therapy suffered increased all-cause and CVD mortality 
(Chodara et al., 2017). None of the published guidelines for RA quantified how to treat patients 
with RA for hyperlipidemia differently than the general population. The CIHR recommended a 
lipid profile within 1-2 years of diagnosis and then at least once every 5 years if low risk (Barber 
et al. 2015). Treatment should be provided to moderate or high risk patients according to national 
guidelines (Barber et al., 2015). A systematic review of current guidelines by Barber et al., 
(2015) summarized that all current literature advised statin therapy as the first line treatment and 
screening and treatment should be based on current national guidelines.  
Mr. Foster’s follow up visit will focus solely on CV risk management. The fact that his 
RA is well controlled is a positive indicator of his CV risk. Mr. Foster should have an 
individualized risk assessment using the FRS and EULAR multiplier (or other general population 
CV risk calculator) and he should be appropriately treated for his uncontrolled hypertension. He 
will need to have lipid screening and blood glucose testing as well as height and weight 
completed for BMI. Mr. Foster will also benefit from counseling on minimizing NSAID use, 
healthy diet, exercise, and the fact that RA increases his CV risks. Future research should focus 
on RA specific CV recommendations, such as how to best ascertain CV risk and how to 
determine optimal thresholds for the use of statins and anti-hypertensives. The role of the 
multidisciplinary care team also needs to be researched as both rheumatology specialists and 
primary care providers are unsure of their role in CV risk management (Barber et al., 2015).  
CARDIOVASCULAR RISK MANAGEMENT  14 
 
Learning Points 
There are many overarching principles that should be applied to every person at risk for 
CV disease and they are not exclusive to RA patients. Although not addressed in the case report, 
RA patients should not be exempt from education regarding lifestyle modifications including the 
benefits of a healthy diet, regular exercise, and smoking cessation. Diabetes screening and 
treatment is also another important factor that was not addressed in this case report, but is 
included in most CV risk predictors such as the Framingham score. Figure 1.0 is an excellent 
resource for primary care providers because it points out the multifactorial risks of CV disease in 
the RA patient (Chodara et al., 2017).  It is of upmost importance for primary care providers to 
recognize the higher risk for CV disease in patients with RA compared to the general population 
and apply the following recommendations in collaboration with a rheumatologist.  
• RA patients benefit from rheumatology consult to have their disease and inflammation 
appropriately managed and adequately controlled in order to decrease their CV risks.  
• NSAIDS and corticosteroids should be prescribed with caution especially for patients 
with known CV risk factors or CV disease.  
• Comprehensive individual CVD risk assessment with risk calculation should be 
performed at least every 5 years or more frequently with major changes in anti-rheumatic 
therapy or high risk patient based on Framingham score (or other general population CV 
risk assessment) with a multiplier of 1.5. 
• Screen for hypertension at every visit and treat elevated blood pressures according to 
JNC 8 and American Heart association guidelines.  
• Screen with a lipid profile within 1-2 years of disease onset (preferably when RA is 
stable) and then at least once every 5 years if normal. Dyslipidemias should be treated 
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